Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta

Bermel, Robert A., You, Xiaojun, Foulds, Pamela, Hyde, Robert, Simon, Jack H., Fisher, Elizabeth, Rudick, Richard A. · 2013 · Annals of Neurology

Abstract

Objective: To identify early predictors of long‐term outcomes in patients with relapsing–remitting multiple sclerosis (RRMS) treated with intramuscular (IM) interferon beta‐1a (IFNβ‐1a). Methods: A multicenter, observational, 15‐year follow‐up study of patients who completed ≥2 years in the pivotal trial of IM IFNβ‐1a for RRMS was conducted. One hundred thirty‐six patients participated in the 15‐year follow‐up (69 originally randomized to IM IFNβ‐1a and 67 to placebo). After the 2‐year clinical trial, treatment was not regulated by study protocol. Disease activity during the 2‐year trial was defined as: ≥2 gadolinium‐enhancing lesions (cumulative) on year 1 and/or year 2 magnetic resonance imaging (MRI); ≥3 new T2 lesions on year 2 MRI compared to baseline; and ≥2 relapses over 2 years. Odds ratios were calculated for early disease activity predicting severe Expanded Disability Status Scale (EDSS) worsening (worst quartile of change, ≥4.5 EDSS points) during the 15‐year interval. Results: The proportion of patients experiencing early disease activity was lower in patients on IM IFNβ‐1a than placebo for all disease activity markers (range, 23.5–29.0% vs 41.0–45.5%). In the IM IFNβ‐1a group, persistent disease activity predicted severe EDSS worsening: gadolinium‐enhancing lesions (odds ratio [OR], 8.96; p < 0.001); relapses (OR, 4.44; p = 0.010); and new T2 lesions (OR, 2.90; p = 0.080). In placebo patients, early disease activity was not as strongly associated with long‐term outcomes (OR range, 1.53–2.62; p = 0.069–0.408). Interpretation: Disease activity despite treatment with IFNβ is associated with unfavorable long‐term outcomes. Particular attention should be paid to gadolinium‐enhancing lesions on IFNβ therapy, as their presence strongly correlates with severe disability 15 years later. The results provide rationale for monitoring IFNβ‐treated patients with MRI, and for changing therapy in patients with active disease. ANN NEUROL 2013.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.23758

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 180

Metadata

Authors
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A.
Venue
Annals of Neurology
Publisher
Wiley
Published
2013-01
Volume
73
Issue
1
Pages
95-103
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2016524113
Cited by
180
References
1
FWCI
9.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta. https://app.cochat.ai/papers/10.1002/ana.23758
The paper
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A. (2013). Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta. Annals of Neurology. https://doi.org/10.1002/ana.23758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.